Contreras-Omaña R, Téllez-Jaén S, López-Covarrubias EF

Language: Spanish
References: 13
Page: 150-154
PDF size: 559.52 Kb.

ABSTRACT

Introduction. Fatty liver disease has become the most common cause of liver injury; it is considered as the hepatic manifestation of metabolic syndrome, and its prevalence is rapidly increasing worldwide. Our objective was to determine if fatty liver disease was the main cause of consultation in our Research Center for Gastrointestinal and Liver Diseases, Hidalgo, Mexico, during the years 2015-2017.
Material and Methods. Descriptive, transversal, observational and retrospective study. We revised and collected medical records from all the patients that attended for medical consultation at our Research Center during the study period. We obtained data related to findings compatible with fatty liver disease in any of its spectrum (NAFLD, NASH, cirrhosis), and we performed statistical analysis by using central tendency and dispersion measures.
Results. From 1,936 revised medical files, we found data compatible with fatty liver in any of its varieties in 454 (23.4%), being 212 male (46.7%) and 242 female (53.3%), with an average age of 46.3 years; data compatible with NASH were found in 131 (6.7%), being female 63 (48.1%) and 68 were male (51.9%), with an average age of 47.9 years. 91 patients presented fatty liver-related cirrhosis (4.7%), being female 54 (59.3%) and male 37 (40.7%), with an average age of 62.2 years.
Discussion. In our Research Center, fatty liver disease, in any of its varieties, covers the 23.4% from the total of causes of medical care, constituting the main cause of attention. It presents predominantly in women, and its NAFLD variety was found to be the most common.

REFERENCES

1. 1.Machado MV., Cortez-Pinto H. Non-Invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013;58:1007-1019.

2. 2.Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, et al. Review article: the diagnosis of non-alcoholic fatty liver disease – avalilability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013; 37: 392-400.

3. 3.Leung CM, Lai LS, Wong WH, Chan KH, Luk YW, Lai JY, et al. Non-alcoholic fatty liver disease: an expanding problem with low levels of awareness in Hong Kong. J Gastroenterol Hepatol 2009; 24: 1786- 1790.

4. 4.Kallman JB, Arsalla A, Park V, Dhungel S, Bhatia P, Haddad D, et al. Screening for hepatitis B, C and nonalcoholic fatty liver disease: a survey of communitybased physicians. Aliment Pharmacol Ther 2009; 29: 1019-1024.

5. 5.Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013; 59: 859-871. 6.Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27-38.

6. 7.Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki- Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010; 42: 320-330.

7. 8.Lonardo A, Carani C, Carulli N, Loria P. 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol 2006;44: 1196-1207.

8. 9.Caballería Ll, Pera G, Arteaga I, Rodríguez L, Aluma A, Morillas RM, et al. High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study. Clin Gastroenterol Hepatol 2018;16: 1138-1145.

9. 10.Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the Epidemic of Nonalcoholic Fatty Liver Disease demonstrates an exponential increase in burden of disease. Hepatology 2018; 67: 123-133.

10. 11.Non-alcoholic Fatty Liver Disease Study Group, Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, et al. Epidemiological modifiers of nonalcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis 2015; 47: 997-1006.

11. 12.Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic Fatty Liver Disease: Evolving paradigms. World J Gastroenterol 2017; 23(36): 6571-6592.

12. 13.Angulo P. Long-Term mortality in NAFLD. Is Liver Histology of any prognostic significance? Hepatology 2010; 51(2): 373-375.

13. 14.Younossi Z, Anstee QM, Marietti M, Hardy T, Eslam M, George J, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15: 11- 20.